Who are OKYO Pharma Limited's main suppliers?

OKYO Pharma Limited (OKYO) key suppliers include: ON-TARGET-THERAPEUTICS-OTT, TUFTS-MEDICAL-CENTRE-TMC, PANETTA-PARTNERS-LIMITED, TMC the metals company Inc., TMC the metals company Inc. and 1 more. View the full supplier network at chainsifter.com/chain/OKYO.

Who are OKYO Pharma Limited's major customers?

OKYO Pharma Limited (OKYO) key customers include: Cardiff Oncology, Inc., Cardiff Oncology, Inc., Hepion Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., Immuron Limited and 10 more. View the full customer network at chainsifter.com/chain/OKYO.

What sector is OKYO Pharma Limited in?

OKYO Pharma Limited (OKYO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

OKYO Pharma Limited Suppliers, Customers & Supply Chain (OKYO)

6Suppliers

15Customers

1Debt Items

16Related Chains

Source-Backed Evidence Depth

OKYO Pharma Limited (OKYO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

3Distinct source URLs

7High confidence

0.755Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

OKYO Pharma Limited Suppliers

Ticker	Name	Confidence	Evidence
ON-TARGET-THERAPEUTICS-OTT	ON-TARGET-THERAPEUTICS-OTT	92%	License Agreement for Urcosimod On Target Therapeutics (OTT) and Tufts Medical Centre (TMC) entered into a license agreement on April 3, 2017
TUFTS-MEDICAL-CENTRE-TMC	TUFTS-MEDICAL-CENTRE-TMC	92%	License Agreement for Urcosimod On Target Therapeutics (OTT) and Tufts Medical Centre (TMC) entered into a license agreement on April 3, 2017
PANETTA-PARTNERS-LIMITED	PANETTA-PARTNERS-LIMITED	90%	On May 22, 2017, OTT entered into a license and sublicense agreement with Panetta Partners Limited, one of our principal stockholders
TMC	TMC the metals company Inc.	90%	We entered into a license agreement with TMC on May 1, 2018, relating to intellectual property and proprietary technology
TMC	TMC the metals company Inc.	90%	Reciprocal relationship from TMC graph: Reciprocal relationship from OKYO graph: We entered into a license agreement with TMC on May 1, 2018, relating to intellectual property and proprietary technology
TLSA	Tiziana Life Sciences Ltd	72%	Reciprocal relationship from TLSA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA g…

OKYO Pharma Limited Customers

Ticker	Name	Confidence	Evidence
CRDF	Cardiff Oncology, Inc.	72%	Reciprocal relationship from CRDF graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from CRDF graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from CRDF g…
CRDF	Cardiff Oncology, Inc.	72%	oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem…
HEPA	Hepion Pharmaceuticals, Inc.	72%	oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem…
HEPA	Hepion Pharmaceuticals, Inc.	72%	Reciprocal relationship from HEPA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from HEPA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from HEPA g…
IMRN	Immuron Limited	72%	oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem…
IMRN	Immuron Limited	72%	Reciprocal relationship from IMRN graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from IMRN graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from IMRN g…
SIGA	SIGA Technologies, Inc.	72%	oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlem…
SIGA	SIGA Technologies, Inc.	72%	Reciprocal relationship from SIGA graph: Reciprocal relationship from OKYO graph: oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates…
TLSA	Tiziana Life Sciences Ltd	72%	imum life of from the date of the conversion of the loan note 27 July 2020 ● % coupon per annum Conversion price of p 17 August 2020 ● % coupon per annum ● Conversion price of p 3 September 2020 ● % …
TLSA	Tiziana Life Sciences Ltd	72%	Reciprocal relationship from TLSA graph: Reciprocal relationship from OKYO graph: imum life of from the date of the conversion of the loan note 27 July 2020 ● % coupon per annum Conversion price of p…
ALPHA-GROUP	ALPHA-GROUP	62%	Group ordinarily finances its activities through cash generated from by private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group’s fina…
BRITISH-VIRGIN-ISLANDS-BUSINESS-COMPANY	BRITISH-VIRGIN-ISLANDS-BUSINESS-COMPANY	62%	tions of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider. Any of the…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates or any future product candidates and to conduct clinical trials, and similar e…
LEASES-THE-GROUP	LEASES-THE-GROUP	62%	consistent with that presented elsewhere. SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS Year ended March 31, 2024 2023 (Loss) attributable to equity holde…
TIZIANA-LIFE-SCIENCES-LTD-TIZIANA-LIFE-SCIENCES-	TIZIANA-LIFE-SCIENCES-LTD-TIZIANA-LIFE-SCIENCES-	62%	Group ordinarily finances its activities through cash generated from by private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group’s fina…

OKYO Pharma Limited Debt Obligations

Instrument	Description	Confidence	Evidence
OKYO-DEBT	Debt stack $185,795	90%	Market cache reports total debt of $185,795.

OKYO Pharma Limited Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for OKYO Pharma Limited.

OKYO Pharma Limited Ownership

Holder	Name	Confidence	Evidence
OKYO-OWNER-WOODLINE-PARTNERS-LP	Woodline Partners LP	90%	13F overlay lists Woodline Partners LP as top holder; 13 tracked holders.

OKYO Pharma Limited Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
TMC	TMC the metals company Inc.	100.00	1	['supplier']
BMY	Bristol-Myers Squibb Company	100.00	2
CRDF	Cardiff Oncology, Inc.	100.00	1	['customer']
BMYMP	Bristol-Myers Squibb Co	100.00	2
HEPA	Hepion Pharmaceuticals, Inc.	100.00	1	['customer']
TLSA	Tiziana Life Sciences Ltd	100.00	1	['customer', 'supplier']
SIGA	SIGA Technologies, Inc.	100.00	1	['customer']
IMRN	Immuron Limited	100.00	1	['customer']
SOPA	Society Pass Incorporated	50.00	2
CTRVP	Hepion Pharmaceuticals, Inc.	50.00	2
NNVC	NanoViricides, Inc.	50.00	2
TMCWW	TMC the metals Co Inc.	50.00	2
ACUT	AccuStem Sciences, Inc.	50.00	2
MANU	Manchester	14.78	2
VKTX	Viking Therapeutics, Inc.	14.78	2
CSLLY	CSL Limited	14.78	2

OKYO Pharma Limited Supply Chain